This study tests how L-isoleucine and sodium docusate enhance simvastatin solubility, suggesting effective excipient combinations.
Simvastatin is a BCS class II drug, which means it has high absorbability but low solubility. The solubility of a drug plays an important role in determining its bioavailability and the effect that it has on the body as a whole. The study objective was to increase the solubility of simvastatin by using two excipients: sodium docusate and L-isoleucine. These excipients were incorporated in a solid dispersion at different ratios, left to dry, dissolved, and tested for increased solubility against a simvastatin calibration curve (which was prepared using a standard solution of simvastatin). The improvement in solubility for a 4:1:1 ratio was 1.49-fold. A 2:1:1 ratio of simvastatin: docusate: isoleucine was increased 7.18-fold, and a 4:3:3 ratio increased the solubility 4.81-fold. The synergistic effect of docusate and isoleucine showed improvement in the solubility of simvastatin at room temperature when incorporated in relatively low ratios.
No takes yet. Share an insight, caveat, or question.
Al-jumaili et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: